Medical Coverage Policy — Cardiointegram (CIG)
Policy governing coverage of Cardiointegram (CIG) as a diagnostic technique for detecting ECG abnormalities in individuals at risk of cardiac ischemia for Commercial Products (Medicare Advantage addressed separately).
No material clinical or coverage changes in this revision.
Coverage Criteria — Cardiointegram (CIG)
Commercial Products — Not Medically Necessary
Covered when ALL of the following are met
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.